Trial Profile

Clinical Exploratory Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Status: Active, no longer recruiting

Phase of Trial: Phase 0

Latest Information Update: 04 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YOLT 202 (Primary)
Indications Alpha 1-antitrypsin deficiency
Focus Adverse reactions; First in man

Most Recent Events

19 Feb 2026 According to YolTech Therapeutics media release, As of February 6th, two participants genetically confirmed as PiZZ genotype, were enrolled and dosed with YOLT-202 in both the 35 mg and 45 mg dose groups.
19 Feb 2026 Interim Results presented at YolTech Therapeutics media release.
30 Sep 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com